ACIP COVID-19 Vaccines Work Group

Dr. Matthew F. Daley, Work Group Chair
May 19, 2022
Trends in number of COVID-19 cases in the United States among all persons

January 23, 2020 – May 16, 2022
Cases: 82,522,948

Daily Trends in Number of COVID-19 Deaths, United States

January 22, 2020 – May 15, 2022
Deaths: 997,215

7-day average: 266 deaths

Unvaccinated people ages ≥5 years had 10X the risk of dying from COVID-19 in February compared to people vaccinated with at least the primary series.

Unvaccinated people ages ≥12 years had 20X the risk of dying from COVID-19 in February compared to people vaccinated with a primary series and booster dose.

COVID-19 vaccine-preventable deaths

- New analysis predicts vaccines could have prevented at least 318,000 COVID-19 deaths between January 2021 and April 2022
  - What if the pace of vaccination at the point of highest demand last spring for each state was sustained, until vaccination coverage reached 100% of the adult population?

Deaths and vaccination sources: The New York Times and CDC

Pediatric vaccine preventable diseases: Hospitalizations per year in the United States prior to recommended vaccines

<table>
<thead>
<tr>
<th>Age</th>
<th>Hepatitis A&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Varicella&lt;sup&gt;2&lt;/sup&gt; (Chickenpox)</th>
<th>Influenza&lt;sup&gt;3&lt;/sup&gt;</th>
<th>COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time period</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>5–14 years</td>
<td>&lt;20 years</td>
<td>5–17 years</td>
<td>5–11 years</td>
</tr>
<tr>
<td>Oct 2020–Oct 2021</td>
<td>&lt;1</td>
<td>30-80</td>
<td>25</td>
<td></td>
</tr>
</tbody>
</table>

<sup>1</sup> https://www.cdc.gov/mmwr/preview/mmwrhtml/ss5603a1.htm<br>
**Pediatric vaccine preventable diseases:**

**Deaths per year in the United States prior to recommended vaccines**

<table>
<thead>
<tr>
<th></th>
<th>Hepatitis A&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Meningococcal (ACWY)&lt;sup&gt;2&lt;/sup&gt;</th>
<th>Varicella&lt;sup&gt;3&lt;/sup&gt;</th>
<th>Rubella&lt;sup&gt;4&lt;/sup&gt;</th>
<th>Rotavirus&lt;sup&gt;5&lt;/sup&gt;</th>
<th>COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td>&lt;20 years</td>
<td>11–18 years</td>
<td>5–9 years</td>
<td>All ages</td>
<td>&lt;5 years</td>
<td>5–11 years</td>
</tr>
<tr>
<td><strong>Average deaths per year</strong></td>
<td>3</td>
<td>8</td>
<td>16</td>
<td>17</td>
<td>20</td>
<td>66</td>
</tr>
</tbody>
</table>


FDA update
FDA authorizes a COVID-19 vaccine booster dose for children ages 5-11 years

- On May 17, 2022: FDA expanded eligibility for Pfizer-BioNTech COVID-19 vaccine booster dose to children ages 5-11 years
  - FDA amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine, authorizing the use of a single booster dose for administration to individuals 5 through 11 years of age at least five months after completion of a primary series with the Pfizer-BioNTech COVID-19 vaccine

Current recommendations for COVID-19 vaccines
Children ages 5-11 years

Persons who are not moderately to severely immunocompromised

Pfizer-BioNTech (ages 5–11 years)

- Dose 1 (primary)
- 3 weeks
- Dose 2 (primary)

Persons who are moderately to severely immunocompromised

Pfizer-BioNTech (ages 5–11 years)

- Dose 1 (primary)
- 3 weeks
- Dose 2 (primary)
- 4 weeks
- Dose 3 (primary)

Everyone in the age group SHOULD receive the dose
COVID-19 vaccine Work Group activities
April-May 2022

Reviewed data:
- Vaccine response by type of immunocompromise in adults
- Seroprevalence of infection-induced SARS-CoV-2 antibodies
- COVID-19 epidemiology in children ages 5-11 years
- Safety and immunogenicity for Pfizer-BioNTech COVID-19 vaccine booster dose in children ages 5-11 years
- VE data for COVID-19 vaccines in children ages 5-11 years
- Safety data for COVID-19 vaccines in children ages 5-11 years
- Policy discussions around booster doses for children ages 5-11 years
Agenda: Thursday May 19, 2022

- Updates on vaccine effectiveness of COVID-19 vaccines in children ages 5-11 years
  
Dr. Link-Gelles (CDC)

- Updates on safety of COVID-19 vaccines in children ages 5-11 years
  
Dr. Shimabukuro (CDC)

- VaST assessment
  
Dr. Talbot (ACIP, VaST Chair)

Break

- PUBLIC COMMENT

- Safety and immunogenicity of BNT 162b2 booster 10mcg dose in children ages 5-11 years
  
Dr. Sabharwal (Pfizer)

- Updates to the EtR Framework: COVID-19 vaccine booster doses in children ages 5-11 years
  
Dr. Oliver (CDC)

- Discussion

VOTE

COVID-19 vaccine booster doses in children ages 5-11 years
Work Group members

ACIP members
- Matthew Daley (chair)
- Beth Bell
- Grace Lee
- Keipp Talbot
- Oliver Brooks

Ex-officio/government members
- FDA: Doran Fink, Rachel Zhang, Lucia Lee
- NIH: Chris Roberts
- IHS: Uzo Chukwuma
- DOD: Bryan Schumacher
- CMS: Jeff Kelman
- BARDA: Christine Oshansky
- HHS: David Kim

CDC Lead
- Sara Oliver

Liaisons
- AAFP: Jonathan Temte
- AAP: Sean O’Leary
- ACOG: Denise Jamieson (primary), Laura Riley (alternate)
- ACP: Jason Goldman
- ADS: Emily Kahn
- AGS: Ken Schmader
- AIM: Rob Shechter (primary), Jane Zucker (alternate)
- AMA: Sandra Fryhofer
- ANA: Kendra McMillan (primary), Ruth Francis (alternate)
- APhA: Michael Hogue
- ASTHO: Marcus Plescia
- CSTE: Susan Lett, Paul Cieslak, Christine Hahn
- IDSA: Jeff Duchin (primary)

Liaisons, cont’d
- NACCHO: Matt Zahn (primary), Jeff Duchin (alternate)
- NACI: Matthew Tunis (primary), Kelsey Young (alternate)
- NFID: Bill Schaffner (primary), Marla Dalton (alternate)
- NMA: Patricia Whitley-Williams
- SHEA: Marci Drees

Consultants
- Ed Belongia
- Kathy Kinlaw
- Dayna Matthew
- Kathleen Neuzil
- Stanley Perlman
- Peter Szilagyi
- Jose Romero
- Hank Bernstein
CDC participants

- Sarah Meyer
- Evelyn Twentyman
- Tara Anderson
- Amy Blain
- Mary Chamberland
- Katherine Fleming-Dutra
- Monica Godfrey
- Susan Goldstein
- Stephen Hadler
- Elisha Hall
- Valerie Morelli
- Danielle Moulia
- Lauren Roper
- Edwin Shanley
- Megan Wallace
- JoEllen Wolicki
- Amanda Cohn
- Jessica MacNeil
- Elfriede Agyemang
- Karen Broder
- Allison Ciesla
- Kathleen Dooling
- Ashley Fowlkes
- Samuel Graitcer
- Rebecca Greco Kone
- Katherine Grusich
- Rita Helfand
- Joy Hsu
- Terri Hyde
- Jefferson Jones
- Cynthia Jorgensen
- Andrew Kroger
- Ruth Link-Gelles
- Lauri Markowitz
- Kristen Nordlund
- Tamara Pilishvili
- Heather Scobie
- Tom Shimabukuro
- John Su
- Natalie Thornburg
- Melinda Wharton
- Ryan Wiegand
- Janet Wright
- Patricia Yu
- Yon Yu
Thank you!

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.